Moderna Files 8-K on Financial Condition and Operations
Ticker: MRNA · Form: 8-K · Filed: 2024-02-22T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, results-of-operations, SEC-filing
Related Tickers: MRNA
TL;DR
**Moderna just dropped an 8-K on its financials, so keep an eye out for their earnings details!**
AI Summary
Moderna, Inc. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition. The filing indicates that the company, based in Cambridge, MA, with IRS number 81-3467528, is providing current financial information. This report is filed under the Securities Exchange Act of 1934, with a Commission File Number of 001-38753.
Why It Matters
This filing provides investors with updated information on Moderna's financial health and operational performance, which can influence stock valuation and future investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial condition and operations, not indicating any immediate adverse events.
Key Players & Entities
- Moderna, Inc. (company) — Registrant
- February 22, 2024 (date) — Date of earliest event reported
- 001-38753 (string) — Commission File Number
- 81-3467528 (string) — IRS Employer Identification No.
- 200 Technology Square Cambridge, MA 02139 (string) — Address of principal executive offices
FAQ
What is the purpose of this 8-K filing by Moderna, Inc.?
The 8-K filing by Moderna, Inc. is a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, specifically addressing 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was February 22, 2024.
What is Moderna, Inc.'s Commission File Number?
Moderna, Inc.'s Commission File Number is 001-38753.
Where are Moderna, Inc.'s principal executive offices located?
Moderna, Inc.'s principal executive offices are located at 200 Technology Square, Cambridge, MA 02139.
What was Moderna, Inc.'s former company name?
Moderna, Inc.'s former company name was Moderna Therapeutics, Inc., with the name change occurring on August 22, 2016.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-02-22 06:32:03
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market
Filing Documents
- mrna-20240222.htm (8-K) — 30KB
- exhibit9912023q4pressrelea.htm (EX-99.1) — 175KB
- 0001682852-24-000010.txt ( ) — 348KB
- mrna-20240222.xsd (EX-101.SCH) — 2KB
- mrna-20240222_lab.xml (EX-101.LAB) — 23KB
- mrna-20240222_pre.xml (EX-101.PRE) — 12KB
- mrna-20240222_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 22, 2024 , Moderna, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Moderna, Inc. dated February 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MODERNA, INC. Date: February 22, 2024 By: /s/ James M. Mock James M. Mock Chief Financial Officer